Tag: Melanoma

Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Imprime PGG-induced IPD Changes Associated with Stable Disease, Progression-Free Survival and Overall Survival EAGAN, MN — November 8, 2019 — Biothera Pharmaceuticals, Inc. announced today immune pharmacodynamic data from its Phase 2 clinical study evaluating the therapeutic combination of Imprime PGG and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in chemo-refractory metastatic triple...

Read More


Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations Set for November 8 and 9 at Society for Immunotherapy of Cancer (SITC) Annual Meeting EAGAN, MN — November 5, 2019 — Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in triple negative breast cancer and melanoma this week at the Society for Immunotherapy of Cancer annual meeting in the Gaylord...

Read More


Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

EAGAN, MN — May 31, 2017 — Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1, the company’s ongoing Phase 2 clinical trial in advanced melanoma/triple negative breast cancer, will be presented at the 2017 ASCO Annual Meeting, taking place in Chicago, IL, June 2-6, 2017. The ASCO presentation details are as follows: Session Date & Time: Monday, June 5, 2017,...

Read More


Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study to combine therapies in patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) EAGAN, MN — February 23, 2017 — Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in combination with the Merck (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with...

Read More